Chiron Real Estate Inc

Aktienanalyse zu Chiron Real Estate Inc (XRN)

$30.160

+1.390 (+4.61%)Zum Schluss

Loading chart…
Hoch
30.240
Eröffnung
28.730
Volumengewichteter Durchschnittskurs
29.71
Volumen
363.19K
Marktkap.
—
Tief
28.730
Umsatz
10.79M
EV/EBITDA, TTM
11.11

Chiron Real Estate Inc. is an internally managed real estate investment trust (REIT) that owns healthcare facilities leased to physician groups and regional and national healthcare systems and seniors housing communities. The Company's seniors' housing includes independent living communities, assisted living communities, memory care communities, and active adult communities. The Company holds its facilities and conducts its operations through its limited partnership subsidiary, Chiron Real Estate LP (the Operating Partnership). The Company owns 91.3% of the outstanding common operating partnership units (OP Units), with the remaining 8.7% owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services in exchange for OP Units. Its investment portfolio consists of healthcare facilities, primarily outpatient medical facilities, seniors housing operating portfolio (SHOP) assets, joint ventures and other investments.

www.chironre.com

KI-Analyse of Chiron Real Estate Inc (XRN)

Halten

Chiron Real Estate Inc (XRN) is currently trading at $30.34, which is significantly below the average analyst price target of $43, indicating potential upside. However, the stock has a very low RSI of 6.158, suggesting it is oversold, but this could also indicate underlying issues. The company reported a remarkable net income of $63.29 million in Q2 2026, showing strong recovery, but it also has a forward P/E ratio of 714.29, indicating potential overvaluation concerns. Given these mixed signals, it is prudent to hold rather than buy at this time.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Chiron Real Estate Inc (XRN) beträgt 714.29, verglichen mit dem 5-Jahres-Durchschnitt von 295.18.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
295.18
Aktuelles P/E
714.29
Überbewertet
516.80
Unterbewertet
73.56

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
12.43
Aktuelles EV/EBITDA
11.11
Überbewertet
14.33
Unterbewertet
10.52

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
3.68
Aktuelles P/S
2.81
Überbewertet
4.76
Unterbewertet
2.60

Whales, die XRN halten

H

Heartland Advisors, Inc.

+ HältXRN

+3.20%

3-Monats-Rendite

Event-Zeitleiste

2026-10-07 (ET)

16:30:00

Chiron Real Estate Appoints Charles P. Fitzgerald as Chairman of the Board

2026-08-05 (ET)

17:30:00

Chiron CEO Highlights Progress in Capital Allocation and Investments

2026-08-03 (ET)

17:00:00

Chiron Appoints Matthew Whitlock as Chief Investment Officer

2026-07-17 (ET)

17:00:00

Chiron Real Estate Appoints New Executives

2026-07-14 (ET)

16:30:00

Chiron Real Estate Appoints New Executive Team

News

XRN FAQ – beantwortet von Alphio AI

Chiron Real Estate Inc. is an internally managed real estate investment trust (REIT) that owns healthcare facilities leased to physician groups and regional and national healthcare systems and seniors housing communities. The Company's seniors' housing includes independent living communities, assisted living communities, memory care communities, and active adult communities. The Company holds its facilities and conducts its operations through its limited partnership subsidiary, Chiron Real Estate LP (the Operating Partnership). The Company owns 91.3% of the outstanding common operating partnership units (OP Units), with the remaining 8.7% owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services in exchange for OP Units. Its investment portfolio consists of healthcare facilities, primarily outpatient medical facilities, seniors housing operating portfolio (SHOP) assets, joint ventures and other investments. It operates in the Real Estate sector.

Chiron Real Estate Inc (XRN) is currently trading at $30.34, which is significantly below the average analyst price target of $43, indicating potential upside. However, the stock has a very low RSI of 6.158, suggesting it is oversold, but this could also indicate underlying issues. The company reported a remarkable net income of $63.29 million in Q2 2026, showing strong recovery, but it also has a forward P/E ratio of 714.29, indicating potential overvaluation concerns. Given these mixed signals, it is prudent to hold rather than buy at this time.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln